CD274 and urinary bladder carcinoma: Based on KEYNOTE-052 and KEYNOTE-361 results, the FDA issued an alert to health care professionals and oncology clinical investigators due to the substantial uncertainty concerning efficacy as a monotherapy to treat bladder cancer patients whose tumor express low (TPS < 10%) amounts of PD-L1 [44].